BUSINESS● LOWSep 8 · Sep 8, 2026, 2:26 PM
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha Tech · global
Amgen's stock has fallen due to a trial setback for Novartis's heart therapy and a subsequent downgrade by BMO. This illustrates how news from a competitor can impact a company's market valuation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS27m agoLufthansa faces €2 billion extra fuel bill as Iran war keeps prices highEuroNews [en]BUSINESS32m agoElon Musk's next target: A major shake-up of America's wireless marketAxios